New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
暂无分享,去创建一个
[1] R. Cody,et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. , 1985, Journal of the American College of Cardiology.
[2] D. Mancini,et al. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. , 1985, Circulation.
[3] H. White,et al. Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. , 1985, The American journal of cardiology.
[4] S. Rubin,et al. MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure. , 1985, Journal of the American College of Cardiology.
[5] P. Reddy,et al. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. , 1985, Journal of the American College of Cardiology.
[6] D. Baim,et al. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. , 1985, Circulation.
[7] F. Shellock,et al. Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. , 1985, American heart journal.
[8] B. Massie,et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. , 1985, Circulation.
[9] J. Franciosa. Intravenous amrinone: an advance or a wrong step? , 1985, Annals of internal medicine.
[10] R. Cody,et al. Acute dose range study of milrinone in congestive heart failure. , 1985, The American journal of cardiology.
[11] E. Braunwald,et al. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. , 1985, The Journal of clinical investigation.
[12] W. Parmley,et al. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure. , 1985, Journal of the American College of Cardiology.
[13] F. Shellock,et al. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement. , 1985, Circulation.
[14] M. Winniford,et al. Assessment of the inotropic and vasodilator effects of amrinone versus isoproterenol. , 1984, The American journal of cardiology.
[15] D. Baim,et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. , 1984, Circulation.
[16] M. Packer,et al. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.
[17] W. Laskey,et al. Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure. , 1984, Journal of the American College of Cardiology.
[18] W. Parmley,et al. Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure. , 1984, American heart journal.
[19] W. Parmley,et al. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. , 1984, Journal of the American College of Cardiology.
[20] M. Packer,et al. Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. , 1984, American Journal of Cardiology.
[21] F. Shellock,et al. Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure. , 1984, American heart journal.
[22] C. Leier,et al. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. , 1984, Journal of the American College of Cardiology.
[23] G. Naccarelli,et al. Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. , 1984, American Journal of Cardiology.
[24] J. F. Lang,et al. Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failure. , 1984, The American journal of cardiology.
[25] J. Cohn,et al. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. , 1984, Journal of the American College of Cardiology.
[26] M. Webb-Peploe,et al. Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. , 1984, British heart journal.
[27] E. Sonnenblick,et al. Should the failing heart be stimulated? , 1984, The New England journal of medicine.
[28] J. Franciosa. Exercise testing in chronic congestive heart failure. , 1984, The American journal of cardiology.
[29] M. Gerold,et al. Cardiovascular Profile of Ro 13–6438, a Novel Positive Inotropic Agent with Vasodilating Properties , 1984, Journal of cardiovascular pharmacology.
[30] R. Muggli,et al. Studies on the Mechanism of Positive Inotropic Activity of Ro 13–6438, a Structurally Novel Cardiotonic Agent with Vasodilating Properties , 1984, Journal of cardiovascular pharmacology.
[31] J. Ansell,et al. Amrinone-induced thrombocytopenia. , 1984, Archives of internal medicine.
[32] M. Sutton,et al. Amrinone in the treatment of chronic cardiac failure. , 1984, Journal of the American College of Cardiology.
[33] C. Antzelevitch,et al. The effects of milrinone on conduction, reflection, and automaticity in canine Purkinje fibers. , 1984, Circulation.
[34] M. Crawford,et al. Positive inotropic and vasodilator effects of MDL 17,043 in patients with reduced left ventricular performance. , 1984, The American journal of cardiology.
[35] S. Rendig,et al. Positive Inotropic Action of Amrinone: Effect of Elevated External Ca2+ , 1984, Journal of cardiovascular pharmacology.
[36] C. Sweet,et al. Responses to Amrinone in Isolated Cardiac Muscles from Cat, Rabbit, and Guinea Pig , 1984, Journal of cardiovascular pharmacology.
[37] M. Webb-Peploe,et al. The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure. , 1984, British journal of clinical pharmacology.
[38] M. Miyazaki,et al. Responses of isolated dog arteries to amrinone. , 1984, Cardiovascular research.
[39] R. C. Dage,et al. Studies on the Mechanism of the Cardiotonic Activity of MDL 19205: Effects on Several Biochemical Systems , 1984, Journal of cardiovascular pharmacology.
[40] H. Cheng,et al. In Vitro and In Vivo Assessment of the Cardiovascular Effects of the Cardiotonic Drug MDL 19205 , 1984, Journal of cardiovascular pharmacology.
[41] C. P. Hsieh,et al. Cardiovascular Properties of a New Cardiotonic Agent, MDL 19205 , 1984, Journal of cardiovascular pharmacology.
[42] Piwonka Rw,et al. Electrophysiological actions of amrinone in dogs with cardiac lesions. , 1983 .
[43] Piwonka Rw,et al. In vitro electrophysiologic properties of amrinone in mammalian cardiac tissue. , 1983 .
[44] E. Sonnenblick,et al. Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise. , 1983, The American journal of cardiology.
[45] I. Kodama,et al. Electrical and Mechanical Effects of Amrinone on Isolated Guinea Pig Ventricular Muscle , 1983, Journal of cardiovascular pharmacology.
[46] R. Arbogast,et al. Hemodynamic Effects of MDL 17,043, a New Cardiotonic Agent, in Patients with Congestive Heart Failure: Comparison with Sodium Nitroprusside , 1983, Journal of cardiovascular pharmacology.
[47] E. Sonnenblick,et al. Improvement in exercise capacity despite cardiac deteriora tion: nonivasive assessment of long-term therapy with amrinone in severe heart failure. , 1983, American heart journal.
[48] R. Bernard,et al. Hemodynamic and clinical response to three-day infusion of sulmazol (AR-L 115 BS) in severe congestive heart failure. , 1983, Chest.
[49] E. Braunwald,et al. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. , 1983, The New England journal of medicine.
[50] R. Ferrari,et al. Cardiotonic Activity of Milrinone, a New and Potent Cardiac Bipyridine, on the Normal and Failing Heart of Experimental Animals , 1983, Journal of cardiovascular pharmacology.
[51] G. Stankus,et al. Characterization of the Cardiotonic Effects of Milrinone, a New and Potent Cardiac Bipyridine, on Isolated Tissues from Several Animal Species , 1983, Journal of cardiovascular pharmacology.
[52] G. Maréchal,et al. Effects of Dobutamine and Sulmazol (AR‐L115 BS) on Myocardial Metabolism and Coronary, Femoral, and Renal Blood Flows: A Comparative Study in Normal Dogs and in Dogs with Chronic Volume Overload , 1983, Journal of cardiovascular pharmacology.
[53] R. Magorien,et al. Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.
[54] E. Sonnenblick,et al. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. , 1983, Journal of the American College of Cardiology.
[55] M. Wilén,et al. Adverse effects of long-term amrinone administration in congestive heart failure. , 1983, American heart journal.
[56] M. Webb-Peploe,et al. Side effects of amrinone therapy. , 1983, British heart journal.
[57] E. Sonnenblick,et al. Sustained Hemodynamic and Clinical Effects of a New Cardiotonic Agent, WIN 47203, in Patients with Severe Congestive Heart Failure , 1983, Circulation.
[58] B. Massie,et al. Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.
[59] P. Reddy,et al. The Acute Hemodynamic Effects of a New Agent, MDL 17,043, in the Treatment of Congestive Heart Failure , 1983, Circulation.
[60] R. Myerburg,et al. Amrinone Relaxes Potassium‐Induced Contracture of Failing Right Ventricular Muscle of Cats , 1983, Journal of cardiovascular pharmacology.
[61] E. R. Garrett,et al. Nonlinear pharmacokinetics of the new positive inotropic agent sulmazole in the dog. , 1983, Journal of pharmaceutical sciences.
[62] D. Coltart,et al. Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. , 1983, British heart journal.
[63] E. Sonnenblick,et al. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. , 1983, The American journal of cardiology.
[64] N. Kondo,et al. A Protective Effect of Coenzyme Q10 on Isolated Rabbit Ventricular Muscle Under Hypoxic Condition , 1982, Journal of cardiovascular pharmacology.
[65] N. Taira,et al. The improvement of cardiac performance by amrinone, a new cardiotonic drug, in an experimental failing heart preparation of the dog. , 1982, Japanese heart journal.
[66] H. Adams,et al. Amrinone Activates K+‐Depolarized Atrial and Ventricular Myocardium of Guinea Pigs , 1982, Circulation research.
[67] L. Lesko,et al. Acute Pharmacodynamics and Pharmacokinetics of Oral Amrinone , 1982, Journal of clinical pharmacology.
[68] B. Carlin,et al. Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure , 1982, Journal of clinical pharmacology.
[69] H. Cheng,et al. Characterization of the Cardiovascular Activities of a New Cardiotonic Agent, MDL 17043 (1,3‐Dihydro-4‐methyl-5-[4-(methylthio)-benzoyl]-2H‐imidazol-2‐one) , 1982, Journal of cardiovascular pharmacology.
[70] N. Taira,et al. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. , 1982, The Journal of pharmacology and experimental therapeutics.
[71] L. Roncoroni,et al. Cardiovascular Effects of AR‐L115 BS in Conscious Dogs With and Without Chronic Congestive Heart Failure , 1982, Journal of cardiovascular pharmacology.
[72] C. P. Hsieh,et al. Cardiovascular Properties of a New Cardiotonic Agent: MDL 17,043 (1,3‐Dihydro-4‐methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol‐2-one) , 1982, Journal of cardiovascular pharmacology.
[73] E. Sonnenblick,et al. Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. , 1982, The American journal of medicine.
[74] E. Sonnenblick,et al. Acute Substantial Benefit of Inotropic Therapy with Amrinone on Exercise Hemodynamics and Metabolism in Severe Congestive Heart Failure , 1981, Circulation.
[75] E. Braunwald,et al. Problems in assessment of new pharmacologic agents for the heart failure patient. , 1981, American heart journal.
[76] E. Sonnenblick,et al. Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs. , 1981, The American journal of cardiology.
[77] E. Sonnenblick,et al. Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. , 1981, The American journal of cardiology.
[78] A. Fishman,et al. Amrinone and exercise performance in patients with chronic heart failure. , 1981, The American journal of cardiology.
[79] E. Sonnenblick,et al. Relationship between amrinone plasma concentration and cardiac index , 1981, Clinical pharmacology and therapeutics.
[80] J. Satriano,et al. The effects of amrinone on transport and cyclic AMP metabolism in toad urinary bladder. , 1981, The Journal of pharmacology and experimental therapeutics.
[81] H. Sebening,et al. The comparison of the effects of AR-L 115 BS and dobutamine in patients with severe cardiac failure. , 1981, Arzneimittel-Forschung.
[82] R. Huxtable,et al. Differential effects of amrinone on contractility and taurine influx in rat and guinea pig hearts. , 1980, European journal of pharmacology.
[83] J. Parker,et al. Effects of amrinone, a cardiotonic drug, on calcium movements in dog erythrocytes. , 1980, The Journal of clinical investigation.
[84] E. Braunwald,et al. Effects of amrinone on experimental acute myocardial ischaemic injury. , 1980, Cardiovascular research.
[85] E. Braunwald,et al. Effects of Amrinone on Myocardial Energy Metabolism and Hemodynamics in Patients with Severe Congestive Heart Failure Due to Coronary Artery Disease , 1980, Circulation.
[86] J. Cohn. Progress in vasodilator therapy for heart failure. , 1980, The New England journal of medicine.
[87] E. Braunwald,et al. Oral amrinone in refractory congestive heart failure. , 1980, The American journal of cardiology.
[88] I. Grupp,et al. Direct vasodilator and positive inotropic actions of amrinone. , 1980, Journal of molecular and cellular cardiology.
[89] E. Sonnenblick,et al. Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. , 1980, The American journal of cardiology.
[90] G. Y. Lesher,et al. Cardiotonic Activity of Amrinone–Win 40680 [5‐Amino‐3,4f‐bipyridin‐6(lH)‐one] , 1979, Circulation research.
[91] A. Katz. A new inotropic drug: its promise and a caution. , 1978, The New England journal of medicine.